Friday’s open arrives with a loaded calendar: the September jobs report at 8:30 a.m. ET, Tesla’s third-quarter deliveries, and a fresh round of after-hours shocks. Synaptics is trading on a rewritten $5.7 billion cash deal, Nike is sliding on a weak full-year forecast, and Mattel just posted its biggest one-day gain since 1996 on takeover chatter. These are the stocks to watch tomorrow, built around smaller and lesser-known names with real catalysts instead of the usual mega-cap crowd.
Stocks to Watch Tomorrow: Market Snapshot for Thursday, Oct. 1, 2026
Wall Street finished the first day of the fourth quarter with modest gains after clawing back early losses as Treasury yields retreated from their highest levels in more than 20 years. The 10-year yield touched about 5.34%, its highest since April 2002, before easing to roughly 5.24% by the close. Small caps led, and AI and semiconductor names carried the tape again while banks and rate-sensitive groups struggled.
| Metric | Thursday’s Reading |
| S&P 500 | 7,666.45 (+0.19%); still below the August record near 7,817 |
| Nasdaq Composite | 26,871.60 (+0.04%) |
| Dow Jones Industrial Average | 50,926.56 (+20.51 pts, +0.04%) |
| Russell 2000 | ~2,806 (+0.35%) |
| 10-Year Treasury Yield | ~5.24% close (intraday high ~5.34%) |
| WTI Crude / Brent | $92.87 (+2.71%) / $102.31 (+4.37%) after China suspended fuel exports |
| Gold | ~$4,203 |
| VIX | ~16.4 |
| Jobless Claims / ISM Manufacturing | 197,000 / 54.5 (prices-paid index jumped to 77.9) |
| August Core PCE | 3.0% year over year vs. 3.3% expected |
Friday’s calendar: September nonfarm payrolls hit at 8:30 a.m. ET with a consensus near 84,000 jobs and unemployment steady near 4.1%. Tesla’s Q3 delivery report is also due, with consensus near 462,000 vehicles. A hot wage number would revive Fed hike odds, which sit near 27% for the Oct. 27–28 meeting after September’s quarter-point hike. A soft print would ease them. For how rate expectations move small caps in a week like this, see our earlier Fed-week stocks-to-watch playbook.
1. Synaptics (SYNA) | Closed $106.15, Up ~13%–16% After Hours
The Mystery Bidder That Rewrote a $7 Billion Merger
Synaptics jumped roughly 16% in after-hours trading after onsemi switched its June stock deal to an all-cash $123-per-share offer. The amendment followed an unsolicited competing proposal from an unnamed third party.
| Metric | Value |
| Last Close (Oct. 1) | $106.15 |
| After-Hours Move | ~+13% to +16% (≈$120–$123) |
| 52-Week Range | $58.28 – $149.11 |
| Market Cap | ~$4.9B at close (calculated); deal values it near $5.7B |
| P/E / Dividend | N/M (GAAP loss) / None |
| YTD / Volume | ~+43% / average volume ~620K shares |
| Analyst View | “Hold” consensus; average target ~$124–$130 (range $90–$170) |
| Support Levels | $106.15 (close); $97–$103 (late-September trading range) |
| Resistance Levels | $123 (cash offer, the natural ceiling unless a rival bids); $149.11 (52-week high) |
Catalyst: Onsemi’s revised $123 cash price is about 16% above Thursday’s close and replaces a stock deal that was worth roughly $108 at onsemi’s closing price near $80.
Latest News: The amended deal drops financing as a closing condition and is backed by a $2.45 billion Morgan Stanley term loan. The FTC has already cleared it, and closing is still expected by mid-2027. Onsemi shares rose about 4% in the regular session and roughly 6%–7% after hours.
Technicals: SYNA now behaves like a merger-arbitrage name, so the cash price acts as a ceiling. A move above $123 would signal the market expects a rival bid.
Fundamentals: Synaptics’ human-interface and sensing businesses throw off steady cash, but GAAP earnings are negative, which is why the deal premium dominates the story.
Bull Case: The unnamed bidder is still out there, and a higher counteroffer would break the $123 cap.
Bear Case: Onsemi cut the headline value by about $1.3 billion, and the deal has more than eight months of regulatory risk ahead.
What to Watch Tomorrow:
- How close SYNA opens to the $123 offer price
- Any disclosure about the competing proposal
- Onsemi (ON), which closed near $80 and traded up after hours
Forecast: Expect a tight, arbitrage-driven range just under $123 unless a rival bidder surfaces.
Why This Matters: When a buyer answers a rival bid by switching to cash instead of raising, it signals the board values certainty over price.
2. Nike (NKE) | Closed $35.15, Down 8.7% After Hours
Another Guidance Reset Pushes the Swoosh Toward a 12-Year Low
Nike closed at $35.15, then slid about 8.7% to roughly $32.09 after hours after a revenue miss and a weak fiscal 2027 outlook.
| Metric | Value |
| Last Close (Oct. 1) | $35.15 (-0.71%) |
| After-Hours Move | ~$32.09 (-8.71%) at 7:59 p.m. ET |
| 52-Week Range | $35.02 – $76.97 |
| Market Cap | ~$52.1B |
| P/E / Forward P/E | 16.7 / 21.1 |
| Dividend | $1.64 per year (~4.7% yield at close) |
| Volume / YTD | ~112.8M shares Thursday / roughly -43% to -44% |
| Analyst View | “Hold” (42 analysts); average target ~$45.63 |
| Support Levels | ~$32.09 (after-hours low); $30 (round number) |
| Resistance Levels | $35.02–$35.15 (old 52-week low, now overhead); $36.24 (Thursday’s high) |
Catalyst: Q1 revenue of $11.2 billion missed the $11.32 billion estimate, even though EPS of $0.48 topped the $0.43–$0.44 consensus.
Latest News: Nike guided fiscal 2027 adjusted EPS to $1.15–$1.35 versus a $1.67 consensus and expects revenue to fall by a high-single-digit percentage. Greater China revenue dropped 26%. A new restructuring plan, called Pace, targets about $2.5 billion in savings through fiscal 2031 and includes layoffs. CEO Elliott Hill said the fix will take time.
Technicals: Thursday’s close sat right on the 52-week low, so any gap lower means fresh multi-year lows.
Fundamentals: Gross margin improved to 42.8% and inventories fell 3% to $7.8 billion, but Nike Direct revenue dropped 8% to $4.1 billion.
Bull Case: The dividend yields near 4.7%, margins are improving and the stock is trading near a decade-plus low.
Bear Case: A guide this far below consensus resets earnings expectations, and the turnaround is stretching into fiscal 2028.
What to Watch Tomorrow:
- Whether the open holds the $32 area or breaks toward $30
- Analyst target cuts from a “Hold”-rated Street
- Reaction in peers that sell into China
Forecast: Expect a heavy-volume gap lower, with the first real test being whether buyers defend the low-$30s.
Why This Matters: Nike’s guide shows that even strong cost-cutting can’t hide a shrinking top line.
3. Mattel (MAT) | Closed $15.04, Up 18.8%
Barbie’s Maker Posts Its Biggest Day Since 1996 on a $6 Billion Whisper
Mattel surged on a Wall Street Journal report that Authentic Brands Group has privately discussed an offer above $20 per share, or roughly $6 billion. It was on track for its largest one-day gain since 1996, per Benzinga.
| Metric | Value |
| Last Close (Oct. 1) | ~$15.04 (+18.8% per Yahoo Finance; other trackers show ~+20% to +22%) |
| Prior Close / Day’s Range | $12.66 / $12.40 – $17.22 |
| 52-Week Range | $12.40 – $22.48 |
| Market Cap | ~$4.3B |
| P/E / Dividend | ~11.2 (EPS $1.34) / None |
| Volume | More than 30M shares vs. ~4.4M average |
| Analyst View | Average target ~$18.15 (range $11–$28); mixed Buy/Hold/Sell |
| Support Levels | $12.66 (pre-report close); $12.40 (52-week low hit this morning) |
| Resistance Levels | $17.22 (intraday high); $20 (reported bid level); $22.48 (52-week high) |
Catalyst: The report implies a premium of more than 58% to Wednesday’s close.
Latest News: A formal sale process is not underway, another suitor could emerge, and nothing guarantees Mattel will engage. Chairman and CEO Ynon Kreiz steps down Oct. 2 to become co-CEO of Paramount Skydance’s merged company, and Condé Nast CEO Roger Lynch is Mattel’s next CEO.
Technicals: The stock reversed from a fresh 52-week low at $12.40 to an intraday high of $17.22 in one session, then faded into the close.
Fundamentals: Second-quarter earnings were a miss, with a small loss, and the stock had been sliding before the report.
Bull Case: A $20-plus offer would be roughly 33% above Thursday’s close, and Authentic’s playbook is buying and licensing iconic brands.
Bear Case: No bid is formal, a CEO transition complicates talks, and the stock already prices in a high chance of a deal.
What to Watch Tomorrow:
- Any confirmation or denial from Mattel or Authentic
- Whether shares hold above $15 or fade toward the prior close
- Call volume and short covering
Forecast: Headline-driven and two-sided. Confirmation could push shares toward the high teens, while silence invites a fade.
Why This Matters: A single unconfirmed number, “$20,” is now the anchor for Mattel’s valuation.
4. Vicor (VICR) | Near $318.50, Up ~10% on a Second Guidance Hike
Royalties Turn a Power-Module Maker Into an AI Licensing Story
Vicor surged about 10% after raising its third-quarter sequential growth guidance to more than 30%. It was the second raise in September, and it came from patent royalties.
| Metric | Value |
| Last Price (Oct. 1) | ~$318.50 (+~10%); premarket high ~$324.18 |
| Prior Close | ~$289 |
| 52-Week Range | $47.56 – $382.65 |
| Market Cap / P/E | ~$14.5B (calculated, ~45.6M shares) / ~100x trailing (calculated, EPS ~$3.11) |
| Dividend / Beta | None / ~2.4 |
| Performance | More than doubled YTD at Wednesday’s close; ~+54% over 30 days |
| Analyst View | All five covering firms rate it Buy or better; median target ~$375; Needham target raised to $350 from $320 |
| Support Levels | ~$289 (prior close); ~$250 (late-September breakout zone) |
| Resistance Levels | $324.18 (premarket high); $382.65 (52-week high) |
Catalyst: Higher royalties from its first non-exclusive Vertical Power Delivery license lifted guidance from “more than 20%” to “more than 30%” sequential growth.
Latest News: On Sept. 21, the CEO said four OEMs and hyperscalers have licensed Vicor’s patented power technology. Roth called the higher royalty contribution a sign of more revenue opportunity.
Technicals: The stock has put up several 12%–14% days in recent weeks, and a close above $324 would put the all-time high zone back in view.
Fundamentals: Trailing revenue is about $474 million (+25%) with net income near $145 million. The next report is expected around Oct. 20.
Bull Case: High-margin royalties scale without new factories, and more licensees could follow.
Bear Case: A beta of 2.4 and a triple-digit P/E leave little room for a miss, and royalty timing can be lumpy.
What to Watch Tomorrow:
- Whether VICR holds the $318 area after a 10% day
- A push through $324
- Any disclosure of additional licensees
Forecast: Momentum is strong, but a 54% monthly run makes a pause or pullback toward $289–$300 plausible before Q3 earnings.
Why This Matters: Vicor is showing that a patent portfolio can move guidance faster than a factory expansion.
5. Liquidia (LQDA) | Near $30.26, Down 11% After a 57% Collapse
The Patent Ruling That Erased Half a Biotech in a Day
Liquidia fell 57% on Sept. 30 and another ~11% on Thursday after a Delaware court found its drug Yutrepia infringes two valid claims of United Therapeutics’ ’327 patent.
| Metric | Value |
| Last Price (Oct. 1) | ~$30.26 (-11.2%) |
| Sept. 30 Close | ~$34.09 (-57.2% from ~$79.6) |
| Market Cap | ~$2.71B |
| P/E / Dividend | N/A (not verified) / None |
| Analyst Moves | Raymond James cut to Outperform, target to $53 from $106; BTIG cut to Neutral; TIKR model ~$59 |
| Insider Activity | ~$222.5M of net insider selling over 12 months (GuruFocus) |
| Rival | United Therapeutics (UTHR) rose ~12.6%–13% on the ruling |
| Support Levels | ~$30 (Thursday’s print and round number) |
| Resistance Levels | ~$34.09 (Sept. 30 close); $53 (Raymond James target) |
Catalyst: The court rejected Liquidia’s invalidity arguments on claims 1 and 14, and United Therapeutics is seeking an injunction that could restrict Yutrepia in the PH-ILD indication.
Latest News: A proposed judgment is due within a week. Liquidia plans to appeal and will ask the FDA to drop PH-ILD from the label.
Technicals: The stock was still falling a day after the crash, a sign sellers have not exhausted themselves.
Fundamentals: The ruling threatens a central part of Yutrepia’s commercial case. Raymond James removed PH-ILD from its model but left Yutrepia’s PAH use intact.
Bull Case: Analyst targets of $53–$59 sit far above the price, and an appeal or a narrow remedy could recover part of the loss.
Bear Case: An injunction or an FDA label change would hit revenue directly, and insiders have been heavy sellers.
What to Watch Tomorrow:
- Whether LQDA holds $30 or makes new lows
- Any filing of the proposed judgment or remedy request
- Rebound attempts toward $34
Forecast: Expect extreme volatility until the court sets a remedy; a bounce is possible, but the legal path stays binary.
Why This Matters: A single patent ruling can reprice a company’s entire commercial plan, and the market is still deciding how big the damage is.
6. Twilio (TWLO) | Near $301, Up ~3%, Heading Into the S&P 500
Index Inclusion Is Coming Tuesday, and the Buyers Are Mandatory
S&P Dow Jones Indices said Twilio will join the S&P 500 before the open on Tuesday, Oct. 6, replacing Warner Bros. Discovery. Index funds must buy the stock, and shares edged higher after hours.
| Metric | Value |
| Last Price (Oct. 1) | ~$301 (+~3%; approximate) |
| Prior Close | ~$292 |
| 52-Week Range | $98.44 – $304.75 |
| Market Cap | ~$46B (calculated, ~153.6M shares) |
| P/E / Dividend | ~40x trailing; ~47x forward / None |
| Revenue / Net Income (TTM) | $5.57B (+17.8%) / $1.15B |
| Analyst View | “Buy” consensus; average target ~$263 (range $165–$330); HSBC Sell, $211 |
| Support Levels | ~$292 (prior close) |
| Resistance Levels | $304.75 (52-week high); $300–$330 (TD Cowen $300; Street high $330) |
Catalyst: The S&P 500 addition takes effect before the open on Oct. 6, which means index funds will buy at Monday’s close.
Latest News: TD Cowen lifted its target to $300 from $260 and Rosenblatt to $290 in late September, while HSBC downgraded to Sell on Sept. 25 with a $211 target.
Technicals: The stock sits at the top of its 52-week range and above its 200-day average.
Fundamentals: Earnings have swung from a loss to $1.15 billion of net income in a year, but the stock now trades above the average analyst target.
Bull Case: Forced index buying plus strong growth can keep pushing shares toward the $304.75 high.
Bear Case: The stock is above consensus targets, and “buy the rumor, sell the inclusion” often reverses after the effective date.
What to Watch Tomorrow:
- Whether TWLO makes a new $304.75 high
- Volume as index managers position
- More analyst target hikes
Forecast: Expect upward pressure into Monday’s close, then a risk of a fade once the buying is done.
Why This Matters: Index inclusion creates predictable demand, but the price already reflects much of it.
7. Cognizant (CTSH) | Closed ~$61.82, Up 11.2%
Accenture’s Blowout Turns an Overlooked IT-Services Stock Into a Mover
Cognizant jumped about 11% after Accenture’s results. Accenture reported Q4 revenue of $18.7 billion and bookings of $22.2 billion, and raised its fiscal 2027 outlook.
| Metric | Value |
| Last Price (Oct. 1) | ~$61.82 (+11.2%) |
| Prior Close / Day’s Range | ~$55.60 / $60.06 – $64.74 |
| 52-Week Range | $37.08 – $87.03 (about 29% below the high) |
| Market Cap | ~$27.8B |
| P/E / Dividend | ~12.3 / $1.30 per year (~2.1% yield, calculated) |
| Volume / Beta | Average ~8.2M shares / ~0.29 |
| Analyst View | Mixed Buy/Hold; targets ~$62–$64 average; Deutsche Bank $70, Baird $68, JPMorgan $67 |
| Support Levels | $60.06 (day low); ~$55.60 (prior close) |
| Resistance Levels | $64.74 (day high); $70 (Deutsche Bank target) |
Catalyst: Accenture soared about 21% on better-than-expected results and annual revenue growth guidance of 3%–6%, which lifted peers including IBM and Infosys.
Latest News: The stock had already spiked in late September after an Anthropic Claude partnership announcement.
Technicals: The stock closed above its recent range but remains below its 52-week high of $87.03.
Fundamentals: Trailing revenue is about $21.6 billion, the P/E is near 12, and the dividend is about 2%.
Bull Case: A cheap multiple, a steady dividend and renewed confidence in IT-services demand.
Bear Case: An 11% day on a peer’s results can retrace, and the stock had been lagging all year.
What to Watch Tomorrow:
- Whether CTSH holds $60 after the gap
- A move toward $64.74
- Follow-through from Infosys and Capgemini
Forecast: Expect consolidation between $60 and $65 unless the jobs report shakes the market.
Why This Matters: A peer’s earnings can re-rate an entire group, and Cognizant is the cheap member of it.
8. Applied Optoelectronics (AAOI) | Near $106, Up ~6%
The AI Optics Small Cap Rides Fresh FCC Rule Hopes
Optical stocks rose broadly after Morgan Stanley described possible FCC rules that could restrict Chinese-made transceivers. AAOI traded near $106 and is up about 205% this year.
| Metric | Value |
| Last Price (Oct. 1) | ~$106 (+~6%; approximate) |
| Prior Close | ~$99.30 |
| 52-Week Range | $18.50 – $233.67 |
| Market Cap | ~$9.0B (calculated, ~84.9M shares) |
| P/E / Dividend | N/A / None |
| Performance | ~+205% YTD; ~-7.8% over 1 month; ~-18% over 3 months |
| Fundamentals | Q1 data-center revenue $81.4M (+154% y/y); fourth straight record-revenue quarter |
| Support Levels | ~$99.30 (prior close); ~$100 (opening area) |
| Resistance Levels | ~$107.69 (Aug. 31 level); ~$120.95 (early-July level) |
Catalyst: Morgan Stanley’s read on potential FCC optical-transceiver rules would limit Chinese-based modules, with a workaround if U.S. content exceeds 65% of the bill of materials.
Latest News: The CEO has said near-term revenue is bounded by production capacity, so the new Texas facility must ramp quickly.
Technicals: The stock is trading in the middle of its 52-week range and below its 200-day average, a rebound inside a longer pullback.
Fundamentals: Volume ramp of 800G products and U.S.-based manufacturing are the core of the story.
Bull Case: A domestic-content rule would favor a U.S. producer, and hyperscaler demand for 800G and 1.6T optics is strong.
Bear Case: The stock is far below its high, has a history of sharp capital-raise drops, and its revenue is capacity-limited.
What to Watch Tomorrow:
- A close above $107.69
- Moves in Lumentum, Coherent and Corning
- Any FCC rule headlines
Forecast: A volatile range between $99 and $108 is likely until clearer rule details emerge.
Why This Matters: A single regulatory framework could shift the economics of the AI optics supply chain.
9. Grindr (GRND) | Closed ~$14.18, Down 8.1%
A $250 Million Telehealth Bet Sends Shares to a Four-Month Low
Grindr fell about 8% after announcing its acquisition of PurposeMed, parent of HIV-prevention provider Freddie, for $250 million in cash and stock. Shares hit their lowest since June.
| Metric | Value |
| Last Price (Oct. 1) | ~$14.18 (-8.1% per CNBC; other trackers show -7% to -8.8%) |
| Prior Close / Day’s Range | $15.43 / $13.53 – $15.95 |
| 52-Week Range | $9.73 – $18.50 |
| Market Cap | ~$2.5B |
| P/E / Dividend | ~28x (calculated) / None |
| Revenue / EBITDA (TTM) | ~$510M / ~$163M |
| Analyst View | Buy; average target ~$19.50 (Morgan Stanley $20, Raymond James $22, Goldman $19) |
| Support Levels | $13.53 (day low) |
| Resistance Levels | $15.43 (prior close); $15.95 (Thursday’s high) |
Catalyst: The deal pays $190 million in cash and $60 million in stock, plus up to $70 million more in 2028 if Freddie hits 2027 targets.
Latest News: Freddie expects 2026 revenue above $80 million and adjusted EBITDA above $10 million. Closing is expected in Q4.
Technicals: The stock gapped down on the news and closed near its lows, though it remains well above its February low.
Fundamentals: Grindr is profitable and cash-generative, which makes a $250 million bolt-on a meaningful use of cash.
Bull Case: Analysts’ targets sit roughly 37% above the price, and health services could add a new revenue stream.
Bear Case: The move into regulated telehealth adds privacy, compliance and integration risk, and the earnout hinges on 2027 performance.
What to Watch Tomorrow:
- Whether GRND holds $13.53
- Analyst reiterations after the dip
- Any detail on financing the cash portion
Forecast: Likely to chop between $13.50 and $15.40 until investors gain confidence in the deal math.
Why This Matters: A first major acquisition tests whether Grindr can diversify beyond dating without losing focus.
10. Vylor (VYLR) | Debuted Near $66–$70, Up ~3% After Hours
Corteva’s Seed Spin-Off Lands Straight in the S&P 500
Vylor began regular-way trading on Thursday after Corteva spun off its seed and genetics business. It opened at $66 and traded near $70 while Corteva’s own shares fell about 83% mechanically as the unit separated.
| Metric | Value |
| First-Day Price | Opened $66; traded near $70 midday; closing price not confirmed |
| After-Hours Move | ~+3% on S&P 500 inclusion |
| 52-Week Range | N/A (first day of trading) |
| Market Cap | Not confirmed; Corteva lost more than $42B in value in the separation |
| P/E / Dividend | N/A (no trading history) / N/A |
| Index Status | Added to the S&P 500 immediately, replacing Corteva |
| Assets | Pioneer brand; 4,000+ germplasm patents; 2,000+ biotech patents |
| Support Levels | $66 (opening print) |
| Resistance Levels | ~$70 (midday level) |
Catalyst: Corteva shareholders received one Vylor share for every Corteva share held on Sept. 24. Corteva moves to the S&P MidCap 400 before the open on Oct. 6.
Latest News: Index funds had to buy Vylor as soon as it joined the S&P 500, and retail sentiment on Corteva turned extremely bullish on the day.
Technicals: There is no trading history, so levels come only from the opening range. First-week spin-offs often see selling from holders who didn’t want the new stock.
Fundamentals: Vylor holds the world’s largest seed production network and growth platforms in gene editing, hybrid wheat and biofuels.
Bull Case: A pure-play seed leader with a large patent estate and forced index demand.
Bear Case: Spin-offs can face early selling pressure, and there is no earnings or valuation history to anchor the stock.
What to Watch Tomorrow:
- Whether VYLR holds the $66 opening level
- The first analyst initiations
- Corteva (CTVA) trading after its record-low reset
Forecast: Expect volatile price discovery over the first week as spin-off holders and index funds adjust.
Why This Matters: A $42 billion value transfer in one day shows how spin-offs can distort index and portfolio math overnight.
Sector Sentiment Snapshot: What Tomorrow’s Stocks to Watch Reveal
Three themes dominate the tape heading into Friday:
- M&A and takeover premiums: Synaptics and Mattel show how deal headlines can add double-digit moves overnight.
- Guidance gaps: Nike’s miss and Vicor’s raise show that guidance, not the quarter, is moving shares.
- Index mechanics: Twilio and Vylor show how S&P 500 changes create forced demand. For how earnings guidance drives single-stock reactions, see our earnings-season breakdown.
The market is a two-tier tape, with AI and chips doing most of the lifting. Under the surface, fewer than 50% of S&P 500 stocks trade above their 200-day average, and credit spreads are widening even as the S&P 500 sits near records.
Forecast: Friday’s payrolls print is the single largest event risk. A hot number revives hike odds and pressures small caps like Grindr and Liquidia. A soft number could support names with company-specific catalysts. For smaller names that move on news, see our penny-stock watchlists.
At a Glance: Stocks to Watch Tomorrow, Friday, Oct. 2
| # | Ticker | Price Reference | Move | Key Catalyst |
| 1 | SYNA | $106.15 close | ~+13% to +16% AH | $123 cash bid from onsemi; rival proposal |
| 2 | NKE | $35.15 close; ~$32.09 AH | -8.7% AH | Weak FY27 guide; China revenue -26% |
| 3 | MAT | ~$15.04 | +18.8% | Authentic Brands takeover interest above $20 |
| 4 | VICR | ~$318.50 | ~+10% | Second Q3 guidance raise on royalties |
| 5 | LQDA | ~$30.26 | -11.2% (after -57%) | Patent ruling; remedy decision due |
| 6 | TWLO | ~$301 | ~+3% | S&P 500 inclusion effective Oct. 6 |
| 7 | CTSH | ~$61.82 | +11.2% | Accenture results and guidance |
| 8 | AAOI | ~$106 | ~+6% | Optical rally; possible FCC transceiver rules |
| 9 | GRND | ~$14.18 | -8.1% | $250M PurposeMed acquisition |
| 10 | VYLR | $66 open; ~$70 midday | ~+3% AH | Corteva spin-off; S&P 500 addition |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, newly listed and clinical-stage stocks carry elevated risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change. Some prices in this article are approximate or reflect the most recent verified print, as exact closing figures for certain names were not available at the time of writing. After-hours moves can change sharply before the market opens. Support and resistance levels are reference points drawn from recent trading and are not predictions. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
